These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 7515270)

  • 21. [Heparin-associated platelet aggregation syndrome with skin necrosis during hemodialysis].
    Bredlich RO; Stracke S; Gall H; Proebstle TM
    Dtsch Med Wochenschr; 1997 Mar; 122(11):328-32. PubMed ID: 9102281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low molecular weight heparins and heparinoids.
    Eikelboom JW; Hankey GJ
    Med J Aust; 2002 Oct; 177(7):379-83. PubMed ID: 12358583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical cross-reactivity between danaparoid and heparin antibodies successfully managed with bivalirudin.
    Shapiro M; Cohen J; Inbal A; Singer P
    Isr Med Assoc J; 2009 Mar; 11(3):188-90. PubMed ID: 19544713
    [No Abstract]   [Full Text] [Related]  

  • 24. Orgaran (Org 10172): its pharmacological profile in experimental models.
    Meuleman DG
    Haemostasis; 1992; 22(2):58-65. PubMed ID: 1379965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological and clinical studies with Lomoparan, a low molecular weight glycosaminoglycan.
    Nurmohamed MT; Fareed J; Hoppensteadt D; Walenga JM; ten Cate JW
    Semin Thromb Hemost; 1991; 17 Suppl 2():205-13. PubMed ID: 1948091
    [No Abstract]   [Full Text] [Related]  

  • 26. [Delayed hypersensitivity to heparins and heparinoids].
    Nicolie B; Bonneau JC; Le Sellin J; Gay G; Leclere JM; Drouet M
    Allerg Immunol (Paris); 2002 Feb; 34(2):47-50. PubMed ID: 11933754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of heparin and a low-molecular weight heparinoid on PAF-induced airway responses in neonatally immunized rabbits.
    Sasaki M; Herd CM; Page CP
    Br J Pharmacol; 1993 Sep; 110(1):107-12. PubMed ID: 7693273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Thrombopenia induced by heparin: treatment with Org 10172. Tolerability and efficacy].
    Tardy-Poncet B; Reynaud J; Tardy B; Mahul P; Mismetti P; Beraud AM; Rebaud MA; Bayon M; Guyotat D
    Presse Med; 1996 May 4-11; 25(16):751-5. PubMed ID: 8692750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heparin-associated thrombocytopenia (HAT)--still a diagnostic and therapeutical problem in clinical practice.
    Kleinschmidt S; Seyfert UT
    Angiology; 1995 Jan; 46(1):37-44. PubMed ID: 7818155
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Heparin-induced thrombopenia during hemodialysis in intensive care: use of a low molecular weight heparinoid, ORG 10172 (Orgaran)].
    Mahul P; Raynaud J; Favre JP; Jospé R; Décousus H; Auboyer C
    Ann Fr Anesth Reanim; 1995; 14(1):29-32. PubMed ID: 7677282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anticoagulant effects of a low molecular weight heparinoid (Org 10172) in human volunteers and haemodialysis patients.
    ten Cate H; Henny CP; ten Cate JW; Büller HR; Mooy MC; Surachno S; Wilmink JM
    Thromb Res; 1985 Jul; 39(2):211-22. PubMed ID: 3161213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synopsis of the anticoagulant and antithrombotic profile of the low molecular weight heparinoid Org 10172 in experimental models.
    Meuleman DG
    Semin Thromb Hemost; 1989 Oct; 15(4):370-2. PubMed ID: 2479103
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel anti-thrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: a survey of its pharmacological properties in experimental animal models.
    Meuleman DG; Hobbelen PM; van Dedem G; Moelker HC
    Thromb Res; 1982 Aug; 27(3):353-63. PubMed ID: 6182627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.
    Wilde MI; Markham A
    Drugs; 1997 Dec; 54(6):903-24. PubMed ID: 9421696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Thrombocytopenia due to heparin therapy. Use of danaparoid (Orgaran), 13 monocentric cases under authorization of temporary prescription (ATU)].
    Gindre L; de Maistre E; Perrin A; Lecompte T; Hoffman MA
    Therapie; 1997; 52(6):591-7. PubMed ID: 9734113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cross-reactivity study of low molecular weight heparins and heparinoid in heparin-induced thrombocytopenia.
    Vun CM; Evans S; Chong BH
    Thromb Res; 1996 Mar; 81(5):525-32. PubMed ID: 8907311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of intimal hyperplasia after arterial injury by heparins and heparinoid.
    Dryjski M; Mikat E; Bjornsson TD
    J Vasc Surg; 1988 Nov; 8(5):623-33. PubMed ID: 2460647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro cross-reactivity of danaparoid sodium in patients with heparin-induced thrombocytopenia type II undergoing cardiovascular surgery.
    Koster A; Meyer O; Hausmann H; Kuppe H; Hetzer R; Mertzlufft F
    J Clin Anesth; 2000 Jun; 12(4):324-7. PubMed ID: 10960207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anticoagulation in patients with heparin-induced thrombocytopenia type II.
    Harenberg J; Huhle G; Piazolo L; Wang LU; Heene DL
    Semin Thromb Hemost; 1997; 23(2):189-96. PubMed ID: 9200346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thrombosis during the use of the heparinoid Organon 10172 in a patient with heparin-induced thrombocytopenia.
    Insler SR; Kraenzler EJ; Bartholomew JR; Kottke-Marchant K; Lytle B; Starr NJ
    Anesthesiology; 1997 Feb; 86(2):495-8. PubMed ID: 9054269
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.